Florida's Peptide Boom Is a Federal Criminal Risk: What Clinics, Sellers, and Prescribers Need to Know in 2026

Florida is one of the largest peptide markets in the country. Clinics advertise recovery stacks on billboards, telehealth platforms ship vials statewide, and South Florida papers are now running consumer explainers on the trend. The explainers cover the science. They skip the part that matters if you own the clinic, run the pharmacy, or fill the orders.

Here is that part. Most of the popular wellness peptides sold in Florida today are unapproved new drugs. Selling, compounding, or administering them to humans can be charged as a federal crime, and the 2026 headlines that convinced everyone the rules loosened did not change that.

Florida has no peptide-specific statute. That cuts against clinics rather than for them, because regulators reach the same conduct through the Florida Drug and Cosmetic Act and the federal Food, Drug, and Cosmetic Act.

Key Takeaways

• FDA removed twelve peptides from its Category 2 restricted list effective April 23, 2026. Removal is not authorization to compound.
• Florida exposure runs through Fla. Stat. § 499.005 and § 499.0051, with unlicensed practice a third-degree felony under Fla. Stat. § 456.065.
• Federal cases are built on 21 U.S.C. §§ 331, 333, and 355, then stacked with wire fraud under 18 U.S.C. § 1343.
• The Southern District of Florida is among the busiest health care fraud districts in the country, and peptide files are landing there now.
• Nearly every peptide case starts with an inspection, a warning letter, or a subpoena. That window is where the case is decided.

What Changed in 2026, and What Did Not

In late 2023, FDA placed nineteen peptide bulk drug substances into Category 2 of the interim 503A bulks list, the tier for substances the agency believed raised significant safety risks in compounding. That closed the legitimate pharmacy supply for BPC-157, TB-500, CJC-1295, and others. Demand did not drop. It moved to online vendors selling bulk powder under research use only labels.

On February 27, 2026, the Secretary of Health and Human Services announced that roughly fourteen of the nineteen would move back toward legal compounding. Coverage treated that as a green light. Effective April 23, 2026, FDA removed twelve from Category 2, including BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon, after the nominating parties withdrew their nominations. None moved to Category 1.

Bulk powder, sterile water, and a syringe on the same counter are not three separate products. To FDA they are one intended use, and intended use is what turns a research label into an unapproved new drug.

That distinction decides cases. A 503A pharmacy may compound from a bulk substance only if it sits on the 503A bulks list, is a component of an FDA-approved drug, or has a USP or NF monograph. Coming off the restricted list clears none of those three gates. FDA's Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026 to consider seven of the twelve, but a recommendation is not a rule. Rulemaking has to follow.

The operating reality in Florida today is the reality of 2025. A product clearing none of the three gates cannot be lawfully sold or administered for human use.

What Federal Investigators Are Building Right Now

Enforcement is running at both ends of the chain, the supplier and the clinic.

On the supply side, FDA has issued warning letters to vendors selling semaglutide, tirzepatide, and retatrutide as unapproved drugs, and it has rejected the research use only defense outright. Intended use turns on the totality of the marketing. Dosing charts, bacteriostatic water sold with the vial, testimonials, and staff answering protocol questions all establish human use regardless of the label.

FDA Office of Criminal Investigations agents carry badges and search warrant authority. When they appear at a clinic door, the regulatory phase of the matter is already over.

Florida has no peptide-specific statute, which cuts against clinics rather than for them. The Medical Spa Prescription Drug Oversight Act, filed as SB 1728 with House companion HB 1429, would have put med spas handling prescription drugs under Board of Pharmacy inspection authority. It died in subcommittee on March 13, 2026, and it will be back. Until then, regulators use existing tools: Department of Health unlicensed activity cases, Board of Medicine discipline, and the Florida Drug and Cosmetic Act.

Florida Charges Come First

Start with Florida, because a state case can come first and hand the federal government a finished record.

Fla. Stat. § 499.005 makes it a prohibited act to sell, deliver, or hold for sale any drug that is adulterated or misbranded, or to manufacture, repackage, or wholesale drugs without a permit. Fla. Stat. § 499.0051 turns several of those acts into felonies, and Fla. Stat. § 499.03 covers possession of prescription drugs without a valid prescription. Unlicensed practice is a third-degree felony under Fla. Stat. § 456.065, reaching staff who inject outside their scope as readily as an owner. Pharmacy activity without a permit falls under Fla. Stat. § 465.015, an anabolic steroid compound lands in Schedule III under Fla. Stat. § 893.03, and the Attorney General reaches the marketing under Fla. Stat. § 501.204.

The Federal Counts and What Gets Stacked On

Federally, distributing an unapproved new drug violates 21 U.S.C. § 355 and the prohibited acts provision at 21 U.S.C. § 331. Penalties sit at 21 U.S.C. § 333: a strict liability misdemeanor requiring no proof of intent, and a felony carrying up to three years on proof of intent to defraud or mislead. The compounding exemptions at 21 U.S.C. §§ 353a and 353b are conditions the defendant must satisfy.

Those counts are the hook. The exposure comes from what gets attached: mail and wire fraud under 18 U.S.C. §§ 1341 and 1343 at twenty years per count, health care fraud under 18 U.S.C. § 1347 at ten, conspiracy under 18 U.S.C. § 371, smuggling under 18 U.S.C. § 545 for imported product, and money laundering under 18 U.S.C. § 1956. At sentencing the range turns on loss under U.S.S.G. § 2B1.1, with enhancements for victims, mass marketing, sophisticated means, and role. A clinic grossing a few million over three years faces a guideline range that surprises almost everyone.

Five Mistakes That Cost Clients the Case Before It Starts

Talking to agents at the door. FDA Office of Criminal Investigations and HHS-OIG agents do not appear to hear your side. They appear to lock in statements. A false answer is its own felony under 18 U.S.C. § 1001.

Producing records without scoping the subpoena. A grand jury subpoena is a negotiation, not a mail-order form. Counsel narrows scope, preserves privilege, and controls what the government learns and when.

"A grand jury subpoena is a negotiation, not a mail-order form."— Aaron M. Cohen, Principal Attorney

Trusting the research use only label. It has not worked in any published FDA enforcement position I have seen. Clinics reconstituting research powder on site are relying on a defense the agency rejected years ago.

Sanitizing the website after contact. Deleting product pages, protocol PDFs, and social posts after an inspection converts a regulatory problem into an obstruction charge under 18 U.S.C. § 1519, twenty years by itself.

Reading silence as safety. These investigations often run two years or more before anyone is charged. The quiet period is the government building the file, not losing interest.

How These Cases Are Defended

The felony provision requires intent to defraud or mislead. That element is the battlefield. A clinic with documented sourcing, purchase records from a licensed pharmacy, patient-specific prescriptions, and informed consent looks nothing like one that bought powder from an overseas website and mixed it in a back room. That difference lives in records that either exist or do not.

Pre-indictment work sets the outcome. Reconstruct the sourcing chain before the government does, identify which compounding gate the product cleared, and map every marketing claim against the intended use analysis. If a target letter has arrived, that is the moment for a written submission to the AUSA and FDA OCI. Sometimes the objective is not an acquittal. It is keeping the matter administrative.

Why the Timing Is Different Right Now

Three clocks are running, and all three argue for moving early.

The rulemaking clock. The July 2026 committee meeting created a clean regulatory before and after. Conduct today is judged against today's rules, and a future rule adding BPC-157 to the bulks list will not retroactively legalize a 2024 sale.

The limitations clock. The general federal limitations period is five years under 18 U.S.C. § 3282. Conduct from 2022 and 2023, when the gray market grew fastest, is still chargeable.

The legislative clock. Florida's med spa oversight bill returns in 2027 with two years of enforcement behind it. Operators who fix sourcing, licensing, and marketing now will be the compliant ones when inspection authority arrives.

Common Questions

Under Investigation Over Peptides in Florida?

If FDA, DOJ, or a Florida licensing board has contacted you about peptide sourcing, compounding, prescribing, or marketing, the decisions made in the first thirty days shape everything that follows. AMC Defense Law represents clinics, compounding pharmacies, prescribers, distributors, and online sellers in federal investigations and prosecutions, in Florida and nationwide.

Aaron M. Cohen defends clinics, compounding pharmacies, prescribers, and online sellers in federal peptide and compounded drug investigations in the Southern District of Florida and nationwide.

Consultations are confidential. If you or your loved ones have been contacted by federal agents or arrested, call Aaron M. Cohen, 24 hours a day to get help.

This article is provided for general informational purposes only and does not constitute legal advice, does not create an attorney-client relationship, and does not address the specific facts of any individual matter. Regulatory status in this area is changing quickly. Consult a licensed attorney regarding your particular situation before acting on anything described here.